Kevin, thought the same thing when I read about cooperative trials with multi companies involved. I guess ACTC will have to rule with a strong hand and the FDA/NIH will have the other hand on the "purse strings". Both Gottlieb and Woodcock are intelligent and strong leaders and will push for real progress in Alzheimer's treatment.
The other question will be how companies like Biogen who have sunk a ton one money and time into drugs like Aducanumab will react to the new precision medical trials being offered to young upstart competitors. As I said before, no other company could have so great a positive or negative impact on Biogen than can Anavex. IMHO Michel Vounatsos still is maintaining a close eye on us.
"Who truly "owns" the result?" Those who paid to do the research.
"Humanity wins, but will a company/companies and the government? We are still basically capitalist, so I wonder."
Capitalism is the reason humanity will win when 273 gets to market. A first working treatment for alz. and AVXL shareholders will win, as they deserve to. and the govt wins as it doesnt have to pay a fortune to warehouse alz patients in nursing homes.
News 
Market Data 
Discover 
